Co-Authors
This is a "connection" page, showing publications co-authored by JAGANNADHA K SASTRY and PRAMOD N NEHETE.
Connection Strength
4.151
-
Phenotypic and functional characterization of lymphocytes from different age groups of Bolivian squirrel monkeys (Saimiri boliviensis boliviensis). PLoS One. 2013; 8(11):e79836.
Score: 0.468
-
Selective induction of cell-mediated immunity and protection of rhesus macaques from chronic SHIV(KU2) infection by prophylactic vaccination with a conserved HIV-1 envelope peptide-cocktail. Virology. 2008 Jan 05; 370(1):130-41.
Score: 0.307
-
Protection by dendritic cells-based HIV synthetic peptide cocktail vaccine: preclinical studies in the SHIV-rhesus model. Vaccine. 2005 Mar 18; 23(17-18):2154-9.
Score: 0.256
-
Dendritic cells enhance detection of antigen-specific cellular immune responses by lymphocytes from rhesus macaques immunized with an HIV envelope peptide cocktail vaccine. J Med Primatol. 2003 Apr; 32(2):67-73.
Score: 0.223
-
A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glycosphingolipids is common to entry and infection by diverse HIV-1 strains. Antiviral Res. 2002 Dec; 56(3):233-51.
Score: 0.218
-
Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model. Vaccine. 2001 Dec 12; 20(5-6):813-25.
Score: 0.204
-
Presence of HLA-C-restricted cytotoxic T-lymphocyte responses in long-term nonprogressors infected with human immunodeficiency virus. Viral Immunol. 1998; 11(3):119-29.
Score: 0.155
-
A synthetic peptide from the first conserved region in the envelope protein gp160 is a strong T-cell epitope in HIV-infected chimpanzees and humans. Viral Immunol. 1998; 11(3):147-58.
Score: 0.155
-
Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals. J Clin Immunol. 1996 Mar; 16(2):115-24.
Score: 0.137
-
Studies on V3-specific cross-reactive T-cell responses in chimpanzees chronically infected with HIV-1IIIB. AIDS. 1995 Jun; 9(6):567-72.
Score: 0.130
-
Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp 120. Cell Immunol. 1995 Feb; 160(2):217-23.
Score: 0.127
-
Procedures for mucosal immunization and analyses of cellular immune response to candidate HIV vaccines in murine and nonhuman primate models. Methods Mol Biol. 2014; 1184:417-55.
Score: 0.118
-
Use of helper T cell-inducing peptides from conserved regions in HIV-1 env in a noncovalent mixture with a CTL-inducing V3-loop peptide for in vivo induction of long-lasting systemic CTL response. Viral Immunol. 1994; 7(4):189-97.
Score: 0.118
-
Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120. J Virol. 1993 Nov; 67(11):6841-6.
Score: 0.116
-
Induction of human immunodeficiency virus-specific T cell responses in rhesus monkeys by synthetic peptides from gp160. AIDS Res Hum Retroviruses. 1993 Mar; 9(3):235-40.
Score: 0.111
-
Nerium oleander derived cardiac glycoside oleandrin is a novel inhibitor of HIV infectivity. Fitoterapia. 2013 Jan; 84:32-9.
Score: 0.109
-
Functional impairment of central memory CD4 T cells is a potential early prognostic marker for changing viral load in SHIV-infected rhesus macaques. PLoS One. 2011; 6(5):e19607.
Score: 0.098
-
TSLP production by epithelial cells exposed to immunodeficiency virus triggers DC-mediated mucosal infection of CD4+ T cells. Proc Natl Acad Sci U S A. 2009 Sep 29; 106(39):16776-81.
Score: 0.087
-
Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens. Vaccine. 2009 May 26; 27(25-26):3335-41.
Score: 0.084
-
Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine. 2007 Apr 30; 25(17):3302-10.
Score: 0.073
-
Improving the sensitivity of the ELISPOT analyses of antigen-specific cellular immune responses in rhesus macaques. Methods Mol Biol. 2005; 302:153-66.
Score: 0.063
-
A two-codon mutant of cholera toxin lacking ADP-ribosylating activity functions as an effective adjuvant for eliciting mucosal and systemic cellular immune responses to peptide antigens. Vaccine. 2004 Dec 09; 23(4):555-65.
Score: 0.063
-
Extramedullary hematopoiesis in the mandibular lymph node of simian-human immunodeficiency virus-infected rhesus monkeys (Macaca mulatta): a report of three cases. Vet Pathol. 2004 Mar; 41(2):186-90.
Score: 0.060
-
SHIV transmission and susceptibility to re-exposure through social contact following vaccination with an HIV synthetic peptide-cocktail: a case study. J Med Primatol. 2004 Feb; 33(1):10-5.
Score: 0.059
-
Differences in functional immune responses of high vs. low hardy healthy individuals. J Behav Med. 2001 Jun; 24(3):219-29.
Score: 0.049
-
Impairment of antigen-specific cellular immune responses under simulated microgravity conditions. In Vitro Cell Dev Biol Anim. 2001 Apr; 37(4):203-8.
Score: 0.049
-
Corrigendum to "Prime-Boost Vaccination Using Chemokine-Fused gp120 DNA and HIV Envelope Peptides Activates Both Immediate and Long-Term Memory Cellular Responses in Rhesus Macaques". Biomed Res Int. 2020; 2020:5471638.
Score: 0.047
-
A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus. J Infect Dis. 2018 11 05; 218(12):1883-1889.
Score: 0.041
-
Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis. J Control Release. 2018 09 28; 286:315-325.
Score: 0.040
-
Efficacy of sustained delivery of GC-1 from a Nanofluidic system in a spontaneously obese non-human primate: a case study. Biomed Microdevices. 2018 06 18; 20(2):49.
Score: 0.040
-
Critical role of Arg59 in the high-affinity gp120-binding region of CD4 for human immunodeficiency virus type 1 infection. Virology. 2007 Jun 20; 363(1):69-78.
Score: 0.037
-
Expression of human immunodeficiency virus type I tat results in down-regulation of bcl-2 and induction of apoptosis in hematopoietic cells. Oncogene. 1996 Aug 01; 13(3):487-93.
Score: 0.035
-
Cross-reactive cytotoxic T lymphocytes induced by V3 loop synthetic peptides from different strains of human immunodeficiency virus type 1. Virology. 1995 Aug 01; 211(1):261-7.
Score: 0.033
-
Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16. Viral Immunol. 1995; 8(3):165-74.
Score: 0.032
-
Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines. J Virol. 2015 Jan; 89(1):669-75.
Score: 0.031
-
Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV. PLoS One. 2013; 8(7):e67574.
Score: 0.028
-
Rapid in vivo induction of HIV-specific CD8+ cytotoxic T lymphocytes by a 15-amino acid unmodified free peptide from the immunodominant V3-loop of GP120. Virology. 1992 Jun; 188(2):502-9.
Score: 0.026
-
Membrane-permeable dideoxyuridine 5'-monophosphate analogue inhibits human immunodeficiency virus infection. Mol Pharmacol. 1992 Mar; 41(3):441-5.
Score: 0.026
-
Increased inherent intestinal granzyme B expression may be associated with SIV pathogenesis in Asian non-human primates. J Med Primatol. 2011 Dec; 40(6):414-26.
Score: 0.025
-
Prime-boost vaccination using chemokine-fused gp120 DNA and HIV envelope peptides activates both immediate and long-term memory cellular responses in rhesus macaques. J Biomed Biotechnol. 2010; 2010:860160.
Score: 0.023
-
Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS One. 2009; 4(3):e5059.
Score: 0.021
-
Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine. 2007 Dec 17; 25(52):8687-701.
Score: 0.019
-
Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon. Leukemia. 1998 Feb; 12(2):155-63.
Score: 0.010